PL3555097T3 - Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych - Google Patents

Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych

Info

Publication number: PL3555097T3
Authority: PL; Poland
Prior art keywords: pyrrolo; imidazo; inhibitors; pyridine compounds; janus kinases
Prior art date: 2016-12-16

Application number

PL17854175.1T

Other languages

English (en)

Inventor

Tatiana KOUDRIAKOVA

Kevin D. Kreutter

Kristi Leonard

Michele C. Rizzolio

Russell C. Smith

Mark S. Tichenor

Aihua Wang

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-16

Filing date

2017-12-15

Publication date

2022-10-17

2017-12-15 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2022-10-17 Publication of PL3555097T3 publication Critical patent/PL3555097T3/pl

Links

DACYIWKCVUOZIP-UHFFFAOYSA-N 3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,3,5,7,9,11-hexaene Chemical class C1=NC2=NC=CC2=C2N=CN=C21 DACYIWKCVUOZIP-UHFFFAOYSA-N 0.000 title 1
102000015617 Janus Kinases Human genes 0.000 title 1
108010024121 Janus Kinases Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL17854175.1T 2016-12-16 2017-12-15 Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych PL3555097T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201662435609P	2016-12-16	2016-12-16
US201762592680P	2017-11-30	2017-11-30
US201762596607P	2017-12-08	2017-12-08
PCT/US2017/066744 WO2018112379A1 (en)	2016-12-16	2017-12-15	Small molecule inhibitors of the jak family of kinases

Publications (1)

Publication Number	Publication Date
PL3555097T3 true PL3555097T3 (pl)	2022-10-17

Family

ID=61692222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17854175.1T PL3555097T3 (pl)	2016-12-16	2017-12-15	Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych

Country Status (35)

Country	Link
US (5)	US10294226B2 (pl)
EP (2)	EP3555097B1 (pl)
JP (2)	JP7291077B2 (pl)
KR (1)	KR102352462B1 (pl)
CN (1)	CN110088105B (pl)
AU (3)	AU2017377069B2 (pl)
CL (1)	CL2019001626A1 (pl)
CO (1)	CO2019006200A2 (pl)
CR (1)	CR20190282A (pl)
CY (1)	CY1125460T1 (pl)
DK (1)	DK3555097T3 (pl)
EC (1)	ECSP19042688A (pl)
ES (1)	ES2922379T3 (pl)
HR (1)	HRP20220885T1 (pl)
HU (1)	HUE059274T2 (pl)
IL (1)	IL267275B (pl)
JO (1)	JOP20190143B1 (pl)
LT (1)	LT3555097T (pl)
MD (1)	MD3555097T2 (pl)
MX (2)	MX391936B (pl)
MY (1)	MY196260A (pl)
NI (1)	NI201900060A (pl)
NZ (1)	NZ795615A (pl)
PE (1)	PE20191105A1 (pl)
PH (1)	PH12019501254A1 (pl)
PL (1)	PL3555097T3 (pl)
PT (1)	PT3555097T (pl)
RS (1)	RS63500B1 (pl)
SA (1)	SA519402216B1 (pl)
SI (1)	SI3555097T1 (pl)
SM (1)	SMT202200326T1 (pl)
TW (1)	TWI777997B (pl)
UA (1)	UA125042C2 (pl)
WO (1)	WO2018112379A1 (pl)
ZA (1)	ZA201904615B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX390005B (es)	2016-10-03	2025-03-20	Hangzhou Highlightll Pharmaceutical Co Ltd	Inhibidores selectivos de jak1 novedosos y usos de los mismos.
EP3640251B1 (en)	2016-10-24	2021-12-08	Astrazeneca AB	6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
JP7291077B2 (ja)	2016-12-16	2023-06-14	ヤンセンファーマシューティカエヌ．ベー．	Ｊａｋファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TWI831738B (zh)	2016-12-16	2024-02-11	美商瑞塔醫藥有限責任公司	用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
PL3494116T3 (pl)	2017-01-30	2020-04-30	Astrazeneca Ab	Modulatory receptora estrogenowego
US11993574B2 (en)	2018-06-15	2024-05-28	Reata Pharmaceuticals, Inc	Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
US12060340B2 (en)	2018-06-20	2024-08-13	Reata Pharmaceuticals, Inc	Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
WO2020216936A1 (en)	2019-04-24	2020-10-29	Janssen Pharmaceutica Nv	Non-clinical liquid formulations of pan-jak inhibitor
BR112021024533A2 (pt)	2019-06-06	2022-01-18	Highlightll Pharmaceutical Hainan Co Ltd	Método de síntese de composto de furoimidazopiridina, forma cristalina de composto de furoimidazopiridina, e forma cristalina de sal do mesmo
CN110483514B (zh)	2019-09-16	2022-06-14	启元生物(杭州)有限公司	一种氰基取代的环肼衍生物及其应用
US20220372135A1 (en)	2019-09-27	2022-11-24	Disc Medicine, Inc.	Methods for treating myelofibrosis and related conditions
KR102931124B1 (ko)	2020-02-21	2026-02-24	주하이 유나이티드 라보라토리즈 컴퍼니 리미티드	Jak 억제제의 결정형 및 그의 적용
MX2022013258A (es)	2020-04-24	2022-11-14	Astrazeneca Ab	Formulaciones farmaceuticas.
MX2022013391A (es)	2020-04-24	2022-11-30	Astrazeneca Ab	Pauta posologica para el tratamiento del cancer.
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN114149428B (zh) *	2020-09-08	2023-06-13	中国药科大学	吡啶并环类化合物及其制备方法、中间体、组合物和应用
MX2023010642A (es)	2021-03-11	2023-11-28	Janssen Pharmaceutica Nv	Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
CN113292561A (zh) *	2021-05-22	2021-08-24	中国药科大学	一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN114432317A (zh) *	2021-05-31	2022-05-06	广州嘉越医药科技有限公司	吡咯并嘧啶类化合物的用途
CN113861194B (zh) *	2021-11-10	2022-07-05	英维沃化工科技(广州)有限公司	一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6080747A (en)	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
UA67844C2 (uk)	1999-04-23	2004-07-15	Смітклайн Бічам Плс	Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2005529933A (ja)	2002-05-31	2005-10-06	シェーリング　コーポレイション	キサンチンホスホジエステラーゼｖインヒビター多形体
GB0319935D0 (en)	2003-08-26	2003-09-24	Cipla Ltd	Polymorphs
US7737279B2 (en)	2005-05-10	2010-06-15	Bristol-Myers Squibb Company	1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
AU2006266045A1 (en)	2005-07-01	2007-01-11	Wyeth	Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
CN102127078A (zh) *	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
WO2007007919A2 (en) *	2005-07-14	2007-01-18	Astellas Pharma Inc.	Heterocyclic janus kinase 3 inhibitors
CN104592231A (zh)	2008-06-10	2015-05-06	Abbvie公司	新的三环化合物
MX2012002480A (es)	2009-09-03	2012-03-26	Bristol Myers Squibb Co	Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
JP2011066747A (ja) *	2009-09-18	2011-03-31	Panasonic Corp	弾性波フィルタ
PH12012501000A1 (en)	2009-12-01	2013-02-11	Abbvie Inc	Novel tricyclic compounds
RU2711869C3 (ru)	2009-12-01	2022-02-02	Эббви Инк.	Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
RU2012132278A (ru)	2010-01-12	2014-02-20	Ф. Хоффманн-Ля Рош Аг	Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
AU2011214254B2 (en)	2010-02-10	2016-06-09	Genon Biotechnologies Oy	Dual activity kinase domains and uses thereof
WO2013007765A1 (en)	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en)	2012-07-06	2012-08-22	Kalvista Pharmaceuticals Ltd	New polymorph
JP6248948B2 (ja)	2013-02-08	2017-12-20	日産化学工業株式会社	３環性ピロロピリジン化合物及びｊａｋ阻害剤
EP2924026A1 (en)	2014-03-28	2015-09-30	Novartis Tiergesundheit AG	Aminosulfonylmethylcyclohexanes as JAK inhibitors
BR112016023299A8 (pt)	2014-05-14	2021-06-29	Nissan Chemical Ind Ltd	composto tricíclico e inibidor de jak, agente preventivo, terapêutico ou de melhoria para doenças contra as quais inibição de jak é eficaz e para artrite reumatoide, medicamento e utilização desses compostos
ES2753159T3 (es)	2015-05-28	2020-04-07	Theravance Biopharma R&D Ip Llc	Compuestos de naftiridina como inhibidores de quinasa JAK
EP3371332A4 (en)	2015-11-04	2019-04-03	Mayo Foundation for Medical Education and Research	METHOD AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES
JOP20190053A1 (ar)	2016-09-23	2019-03-21	Novartis Ag	مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EP3640251B1 (en)	2016-10-24	2021-12-08	Astrazeneca AB	6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
KR102314286B1 (ko)	2016-12-16	2021-10-21	화이자 인코포레이티드	Glp-1 수용체 작용제 및 이의 용도
ES2941631T3 (es)	2016-12-16	2023-05-24	Lilly Co Eli	Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes
JP7291077B2 (ja)	2016-12-16	2023-06-14	ヤンセンファーマシューティカエヌ．ベー．	Ｊａｋファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP3555050A1 (en)	2016-12-16	2019-10-23	Basf Se	Pesticidal compounds
WO2018109074A1 (en)	2016-12-16	2018-06-21	Nestec Sa	Oligosaccharides for flavour generation
LT3568396T (lt)	2017-01-11	2021-02-10	Leo Pharma A/S	Nauji amino-imidazopiridino dariniai, kaip janus kinazės inhibitoriai ir jų farmacinis panaudojimas
PL3494116T3 (pl)	2017-01-30	2020-04-30	Astrazeneca Ab	Modulatory receptora estrogenowego
MX2019012431A (es)	2017-04-21	2020-08-03	Ikena Oncology Inc	Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CN106881892B (zh)	2017-04-27	2020-10-16	双钱集团（江苏）轮胎有限公司	一种轮胎生产用生胎转移系统
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
WO2020216936A1 (en)	2019-04-24	2020-10-29	Janssen Pharmaceutica Nv	Non-clinical liquid formulations of pan-jak inhibitor

2017
- 2017-12-15 JP JP2019531668A patent/JP7291077B2/ja active Active
- 2017-12-15 PT PT178541751T patent/PT3555097T/pt unknown
- 2017-12-15 UA UAA201908086A patent/UA125042C2/uk unknown
- 2017-12-15 DK DK17854175.1T patent/DK3555097T3/da active
- 2017-12-15 EP EP17854175.1A patent/EP3555097B1/en active Active
- 2017-12-15 MY MYPI2019003389A patent/MY196260A/en unknown
- 2017-12-15 SI SI201731186T patent/SI3555097T1/sl unknown
- 2017-12-15 WO PCT/US2017/066744 patent/WO2018112379A1/en not_active Ceased
- 2017-12-15 KR KR1020197020121A patent/KR102352462B1/ko active Active
- 2017-12-15 MD MDE20191212T patent/MD3555097T2/ro unknown
- 2017-12-15 PL PL17854175.1T patent/PL3555097T3/pl unknown
- 2017-12-15 RS RS20220753A patent/RS63500B1/sr unknown
- 2017-12-15 ES ES17854175T patent/ES2922379T3/es active Active
- 2017-12-15 CR CR20190282A patent/CR20190282A/es unknown
- 2017-12-15 MX MX2019007073A patent/MX391936B/es unknown
- 2017-12-15 LT LTEPPCT/US2017/066744T patent/LT3555097T/lt unknown
- 2017-12-15 TW TW106144095A patent/TWI777997B/zh active
- 2017-12-15 PE PE2019001252A patent/PE20191105A1/es unknown
- 2017-12-15 SM SM20220326T patent/SMT202200326T1/it unknown
- 2017-12-15 AU AU2017377069A patent/AU2017377069B2/en active Active
- 2017-12-15 JO JOP/2019/0143A patent/JOP20190143B1/ar active
- 2017-12-15 HU HUE17854175A patent/HUE059274T2/hu unknown
- 2017-12-15 CN CN201780077753.4A patent/CN110088105B/zh active Active
- 2017-12-15 HR HRP20220885TT patent/HRP20220885T1/hr unknown
- 2017-12-15 US US15/843,642 patent/US10294226B2/en active Active
- 2017-12-15 MX MX2022004474A patent/MX2022004474A/es unknown
- 2017-12-15 NZ NZ795615A patent/NZ795615A/en unknown
- 2017-12-15 EP EP22178880.5A patent/EP4086256A1/en active Pending
2019
- 2019-01-09 US US16/243,874 patent/US10364246B2/en active Active
- 2019-02-12 US US16/274,142 patent/US11059823B2/en active Active
- 2019-02-13 US US16/275,045 patent/US10487083B2/en active Active
- 2019-06-06 PH PH12019501254A patent/PH12019501254A1/en unknown
- 2019-06-12 IL IL267275A patent/IL267275B/en unknown
- 2019-06-12 CL CL2019001626A patent/CL2019001626A1/es unknown
- 2019-06-13 SA SA519402216A patent/SA519402216B1/ar unknown
- 2019-06-14 EC ECSENADI201942688A patent/ECSP19042688A/es unknown
- 2019-06-14 NI NI201900060A patent/NI201900060A/es unknown
- 2019-06-14 CO CONC2019/0006200A patent/CO2019006200A2/es unknown
- 2019-07-15 ZA ZA2019/04615A patent/ZA201904615B/en unknown
2020
- 2020-10-21 AU AU2020257068A patent/AU2020257068A1/en not_active Abandoned
2021
- 2021-06-23 US US17/355,472 patent/US12202831B2/en active Active
2022
- 2022-06-17 AU AU2022204240A patent/AU2022204240B2/en active Active
- 2022-08-02 CY CY20221100530T patent/CY1125460T1/el unknown
2023
- 2023-02-13 JP JP2023019626A patent/JP7493068B2/ja active Active

Also Published As

Publication number	Publication date
PE20191105A1 (es)	2019-08-23
CA3046965A1 (en)	2018-06-21
NZ755404A (en)	2024-10-25
TW201831180A (zh)	2018-09-01
US20190185474A1 (en)	2019-06-20
US20190177322A1 (en)	2019-06-13
CY1125460T1 (el)	2025-05-09
US10364246B2 (en)	2019-07-30
JP7291077B2 (ja)	2023-06-14
ECSP19042688A (es)	2019-06-30
PH12019501254A1 (en)	2020-01-20
US10487083B2 (en)	2019-11-26
MX2019007073A (es)	2019-10-15
EP3555097A1 (en)	2019-10-23
MD3555097T2 (ro)	2022-12-31
JP7493068B2 (ja)	2024-05-30
PT3555097T (pt)	2022-09-22
SA519402216B1 (ar)	2022-10-02
AU2022204240A1 (en)	2022-07-07
LT3555097T (lt)	2022-08-25
WO2018112379A1 (en)	2018-06-21
DK3555097T3 (da)	2022-07-25
US20180170931A1 (en)	2018-06-21
IL267275A (en)	2019-08-29
HRP20220885T1 (hr)	2022-12-09
ES2922379T3 (es)	2022-09-14
AU2017377069B2 (en)	2020-07-23
MX2022004474A (es)	2023-08-15
CO2019006200A2 (es)	2019-06-28
EP4086256A1 (en)	2022-11-09
TWI777997B (zh)	2022-09-21
US10294226B2 (en)	2019-05-21
KR102352462B1 (ko)	2022-01-17
US12202831B2 (en)	2025-01-21
SI3555097T1 (sl)	2022-09-30
MX391936B (es)	2025-03-21
SMT202200326T1 (it)	2022-09-14
AU2017377069A1 (en)	2019-06-20
JP2020502113A (ja)	2020-01-23
RS63500B1 (sr)	2022-09-30
CL2019001626A1 (es)	2019-10-04
US11059823B2 (en)	2021-07-13
ZA201904615B (en)	2021-05-26
JP2023071709A (ja)	2023-05-23
AU2020257068A1 (en)	2020-11-19
HUE059274T2 (hu)	2022-11-28
CN110088105A (zh)	2019-08-02
MY196260A (en)	2023-03-24
NZ795615A (en)	2025-11-28
KR20190086779A (ko)	2019-07-23
US20210340143A1 (en)	2021-11-04
EP3555097B1 (en)	2022-06-15
BR112019011968A2 (pt)	2019-11-05
CN110088105B (zh)	2022-03-18
JOP20190143B1 (ar)	2023-09-17
NI201900060A (es)	2020-03-16
UA125042C2 (uk)	2021-12-29
CR20190282A (es)	2019-08-21
US20190177321A1 (en)	2019-06-13
IL267275B (en)	2021-07-29
AU2022204240B2 (en)	2023-10-05
JOP20190143A1 (ar)	2019-06-13

Publication	Publication Date	Title
PL3555097T3 (pl)	2022-10-17	Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych
IL277576A (en)	2020-11-30	Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
IL265918B (en)	2021-01-31	Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors
SG11202101148UA (en)	2021-04-29	PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
ZA201800771B (en)	2021-05-26	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
IL255305B (en)	2020-05-31	Synthesis of kinase-modulating h1-pyrrolo[3,2-b]pyridine derivatives
DK3478682T3 (da)	2021-09-13	[1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
IL266305B (en)	2021-10-31	History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
PL2958921T3 (pl)	2018-01-31	Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinaz janusowych (jak)
PL3371185T3 (pl)	2021-04-06	Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
PT3712152T (pt)	2021-04-15	Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
SG11201606216UA (en)	2016-09-29	Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors
IL247948B (en)	2019-03-31	7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors
IL290419B (en)	2022-10-01	Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
EP3856743A4 (en)	2022-06-15	SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
IL272988A (en)	2020-04-30	Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
HK40130482A (zh)	2026-04-10	制备咪唑并[1，2-a]吡咯并[2，3-e]吡嗪类化合物及其固态形式的方法